Scienture (NASDAQ:SCNX) Cut to Sell at Wall Street Zen

Scienture (NASDAQ:SCNX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Scienture Stock Performance

NASDAQ:SCNX opened at $0.51 on Friday. The stock has a fifty day moving average price of $0.55 and a 200-day moving average price of $0.98. The company has a market cap of $20.72 million, a price-to-earnings ratio of -0.51 and a beta of 3.00. Scienture has a fifty-two week low of $0.46 and a fifty-two week high of $4.40.

Scienture (NASDAQ:SCNX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.19) EPS for the quarter. The company had revenue of $0.59 million during the quarter.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.